Innovative Medicine: nipocalimab in gMG; RYBREVANT Sub-Q in NSCLC; TREMFYA Sub-Q in UC; TAR-200 NMIBC; icotrokinra in PsO and UC; RYBREVANT in HNC; CAPLYTA in aMDD. MedTech: OTTAVA progression; Advancements across Cardiovascular.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson expects 2H operational sales growth higher than 1H
- Johnson & Johnson raises FY25 operational sales view to $91.6B-$92.4B
- Genmab reports Q1 net sales of Darzalex of $3.24B
- Johnson & Johnson raises quarterly dividend 4.8% to $1.30 from $1.24 per share
- Johnson & Johnson reports Q1 adjusted EPS $2.77, consensus $2.58